Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Successful Use of Single-Dose Rituximab for the Maintenance of Remission in a Patient with Steroid-Resistant Nephrotic Syndrome
Noritomo KurosuHidekazu SugiuraChihiro IwasakiYukari AsamiyaChiari KojimaTakahito MoriyamaMitsuyo ItabashiMisao TsukadaTakashi TakeiTetsuya OgawaTakumi YoshidaKeiko UchidaKen TsuchiyaKosaku Nitta
Author information
JOURNAL OPEN ACCESS

2009 Volume 48 Issue 21 Pages 1901-1904

Details
Abstract

We present the case of a 23-year-old man with steroid-resistant nephrotic syndrome due to minimal change disease who was treated with rituximab. The patient was resistant to conventional therapy. We therefore treated him with a single dose of rituximab (375 mg/m2). One month after the administration of rituximab, complete remission was achieved. However, six months later, the patient was administered a second dose of rituximab as the peripheral B cell counts began to recover. Thereafter, at present, that is, one year after the first rituximab administration, complete remission has been maintained. We conclude that rituximab may be an effective treatment agent for resistant nephrotic syndrome and the peripheral B cell count may be a useful marker in such patients for preventing disease relapse.

Content from these authors
© 2009 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top